Abstract
Most premenopausal women diagnosed with primary breast cancer receive adjuvant chemotherapy, and many experience chemotherapy-induced ovarian failure (CIOF). CIOF is associated with menopausal symptoms, fertility concerns and long-term implications including bone loss. Ironically, CIOF might confer a disease-specific benefit to women whose breast cancers express hormone receptors. Risk factors of CIOF include the woman's age at the time of therapy, and the type, dose and schedule of chemotherapy. Because inherited genetic factors have an important role in determining who will experience CIOF, genetic testing has the potential to provide optimal counselling about risks and possible interventions.
| Original language | English |
|---|---|
| Pages (from-to) | 886-893 |
| Number of pages | 8 |
| Journal | Nature Reviews Cancer |
| Volume | 6 |
| Issue number | 11 |
| DOIs | |
| State | Published - Nov 12 2006 |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
Cite this
Breast cancer treatment and ovarian failure : Risk factors and emerging genetic determinants. / Stearns, Vered; Schneider, Bryan; Henry, N. Lynn; Hayes, Daniel F.; Flockhart, David A.
In: Nature Reviews Cancer, Vol. 6, No. 11, 12.11.2006, p. 886-893.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Breast cancer treatment and ovarian failure
T2 - Risk factors and emerging genetic determinants
AU - Stearns, Vered
AU - Schneider, Bryan
AU - Henry, N. Lynn
AU - Hayes, Daniel F.
AU - Flockhart, David A.
PY - 2006/11/12
Y1 - 2006/11/12
N2 - Most premenopausal women diagnosed with primary breast cancer receive adjuvant chemotherapy, and many experience chemotherapy-induced ovarian failure (CIOF). CIOF is associated with menopausal symptoms, fertility concerns and long-term implications including bone loss. Ironically, CIOF might confer a disease-specific benefit to women whose breast cancers express hormone receptors. Risk factors of CIOF include the woman's age at the time of therapy, and the type, dose and schedule of chemotherapy. Because inherited genetic factors have an important role in determining who will experience CIOF, genetic testing has the potential to provide optimal counselling about risks and possible interventions.
AB - Most premenopausal women diagnosed with primary breast cancer receive adjuvant chemotherapy, and many experience chemotherapy-induced ovarian failure (CIOF). CIOF is associated with menopausal symptoms, fertility concerns and long-term implications including bone loss. Ironically, CIOF might confer a disease-specific benefit to women whose breast cancers express hormone receptors. Risk factors of CIOF include the woman's age at the time of therapy, and the type, dose and schedule of chemotherapy. Because inherited genetic factors have an important role in determining who will experience CIOF, genetic testing has the potential to provide optimal counselling about risks and possible interventions.
UR - http://www.scopus.com/inward/record.url?scp=33750287996&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33750287996&partnerID=8YFLogxK
U2 - 10.1038/nrc1992
DO - 10.1038/nrc1992
M3 - Article
C2 - 17036039
AN - SCOPUS:33750287996
VL - 6
SP - 886
EP - 893
JO - Nature Reviews Cancer
JF - Nature Reviews Cancer
SN - 1474-175X
IS - 11
ER -